FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050194585> ?p ?o ?g. }

• W2050194585 endingPage "29898" @default.
• W2050194585 startingPage "29887" @default.
• W2050194585 abstract "Metastatic melanoma is a deadly skin cancer and is resistant to almost all existing treatment. Vemurafenib, which targets the BRAFV600E mutation, is one of the drugs that improves patient outcome, but the patients next develop secondary resistance and a return to cancer. Thus, new therapeutic strategies are needed to treat melanomas and to increase the duration of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor response. The ERK pathway controls cell proliferation, and Aurora B plays a pivotal role in cell division. Here, we confirm that Aurora B is highly expressed in metastatic melanoma cells and that Aurora B inhibition triggers both senescence-like phenotypes and cell death in melanoma cells. Furthermore, we show that the BRAF/ERK axis controls Aurora B expression at the transcriptional level, likely through the transcription factor FOXM1. Our results provide insight into the mechanism of Aurora B regulation and the first molecular basis of Aurora B regulation in melanoma cells. The inhibition of Aurora B expression that we observed in vemurafenib-sensitive melanoma cells was rescued in cells resistant to this drug. Consistently, these latter cells remain sensitive to the effect of the Aurora B inhibitor. Noteworthy, wild-type BRAF melanoma cells are also sensitive to Aurora B inhibition. Collectively, our findings, showing that Aurora B is a potential target in melanoma cells, particularly in those vemurafenib-resistant, may open new avenues to improve the treatment of metastatic melanoma. Metastatic melanoma is a deadly skin cancer and is resistant to almost all existing treatment. Vemurafenib, which targets the BRAFV600E mutation, is one of the drugs that improves patient outcome, but the patients next develop secondary resistance and a return to cancer. Thus, new therapeutic strategies are needed to treat melanomas and to increase the duration of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor response. The ERK pathway controls cell proliferation, and Aurora B plays a pivotal role in cell division. Here, we confirm that Aurora B is highly expressed in metastatic melanoma cells and that Aurora B inhibition triggers both senescence-like phenotypes and cell death in melanoma cells. Furthermore, we show that the BRAF/ERK axis controls Aurora B expression at the transcriptional level, likely through the transcription factor FOXM1. Our results provide insight into the mechanism of Aurora B regulation and the first molecular basis of Aurora B regulation in melanoma cells. The inhibition of Aurora B expression that we observed in vemurafenib-sensitive melanoma cells was rescued in cells resistant to this drug. Consistently, these latter cells remain sensitive to the effect of the Aurora B inhibitor. Noteworthy, wild-type BRAF melanoma cells are also sensitive to Aurora B inhibition. Collectively, our findings, showing that Aurora B is a potential target in melanoma cells, particularly in those vemurafenib-resistant, may open new avenues to improve the treatment of metastatic melanoma." @default.
• W2050194585 created "2016-06-24" @default.
• W2050194585 creator A5011959227 @default.
• W2050194585 creator A5026369085 @default.
• W2050194585 creator A5045396112 @default.
• W2050194585 creator A5046980148 @default.
• W2050194585 creator A5052823999 @default.
• W2050194585 creator A5064301315 @default.
• W2050194585 creator A5068193783 @default.
• W2050194585 creator A5080197227 @default.
• W2050194585 creator A5083736614 @default.
• W2050194585 creator A5086188478 @default.
• W2050194585 date "2012-08-01" @default.
• W2050194585 modified "2023-10-18" @default.
• W2050194585 title "Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells" @default.
• W2050194585 cites W1948224603 @default.
• W2050194585 cites W1965317739 @default.
• W2050194585 cites W1980368135 @default.
• W2050194585 cites W1994551053 @default.
• W2050194585 cites W1998809103 @default.
• W2050194585 cites W2003729867 @default.
• W2050194585 cites W2004295816 @default.
• W2050194585 cites W2024085992 @default.
• W2050194585 cites W2029335488 @default.
• W2050194585 cites W2030122054 @default.
• W2050194585 cites W2032211985 @default.
• W2050194585 cites W2032809798 @default.
• W2050194585 cites W2040720913 @default.
• W2050194585 cites W2051165598 @default.
• W2050194585 cites W2052677817 @default.
• W2050194585 cites W2056166106 @default.
• W2050194585 cites W2084631434 @default.
• W2050194585 cites W2093908807 @default.
• W2050194585 cites W2095213000 @default.
• W2050194585 cites W2097995306 @default.
• W2050194585 cites W2106942695 @default.
• W2050194585 cites W2112064734 @default.
• W2050194585 cites W2117471298 @default.
• W2050194585 cites W2117476815 @default.
• W2050194585 cites W2125000060 @default.
• W2050194585 cites W2128542677 @default.
• W2050194585 cites W2128598241 @default.
• W2050194585 cites W2132480521 @default.
• W2050194585 cites W2135630561 @default.
• W2050194585 cites W2138099795 @default.
• W2050194585 cites W2143191174 @default.
• W2050194585 cites W2146838968 @default.
• W2050194585 cites W2149972103 @default.
• W2050194585 cites W2157636976 @default.
• W2050194585 cites W2162942873 @default.
• W2050194585 cites W2163188200 @default.
• W2050194585 cites W2164660906 @default.
• W2050194585 cites W2164937682 @default.
• W2050194585 cites W2168881161 @default.
• W2050194585 doi "https://doi.org/10.1074/jbc.m112.371682" @default.
• W2050194585 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3436153" @default.
• W2050194585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22767597" @default.
• W2050194585 hasPublicationYear "2012" @default.
• W2050194585 type Work @default.
• W2050194585 sameAs 2050194585 @default.
• W2050194585 citedByCount "67" @default.
• W2050194585 countsByYear W20501945852012 @default.
• W2050194585 countsByYear W20501945852013 @default.
• W2050194585 countsByYear W20501945852014 @default.
• W2050194585 countsByYear W20501945852015 @default.
• W2050194585 countsByYear W20501945852016 @default.
• W2050194585 countsByYear W20501945852017 @default.
• W2050194585 countsByYear W20501945852018 @default.
• W2050194585 countsByYear W20501945852019 @default.
• W2050194585 countsByYear W20501945852020 @default.
• W2050194585 countsByYear W20501945852021 @default.
• W2050194585 countsByYear W20501945852022 @default.
• W2050194585 countsByYear W20501945852023 @default.
• W2050194585 crossrefType "journal-article" @default.
• W2050194585 hasAuthorship W2050194585A5011959227 @default.
• W2050194585 hasAuthorship W2050194585A5026369085 @default.
• W2050194585 hasAuthorship W2050194585A5045396112 @default.
• W2050194585 hasAuthorship W2050194585A5046980148 @default.
• W2050194585 hasAuthorship W2050194585A5052823999 @default.
• W2050194585 hasAuthorship W2050194585A5064301315 @default.
• W2050194585 hasAuthorship W2050194585A5068193783 @default.
• W2050194585 hasAuthorship W2050194585A5080197227 @default.
• W2050194585 hasAuthorship W2050194585A5083736614 @default.
• W2050194585 hasAuthorship W2050194585A5086188478 @default.
• W2050194585 hasBestOaLocation W20501945851 @default.
• W2050194585 hasConcept C121608353 @default.
• W2050194585 hasConcept C126322002 @default.
• W2050194585 hasConcept C141937037 @default.
• W2050194585 hasConcept C1491633281 @default.
• W2050194585 hasConcept C184235292 @default.
• W2050194585 hasConcept C20552341 @default.
• W2050194585 hasConcept C2776131300 @default.
• W2050194585 hasConcept C2777658100 @default.
• W2050194585 hasConcept C2780808130 @default.
• W2050194585 hasConcept C2781249067 @default.
• W2050194585 hasConcept C29537977 @default.
• W2050194585 hasConcept C2994587330 @default.
• W2050194585 hasConcept C45472230 @default.

• next